NextCell Pharma AB (NXTCL.ST)
SEK 2.42
(-13.57%)
SEK 2.42
(-13.57%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -43.17 Million SEK | -5.29% |
| 2023 | -41 Million SEK | -17.07% |
| 2022 | -35.02 Million SEK | -41.11% |
| 2021 | -24.82 Million SEK | -40.21% |
| 2020 | -17.7 Million SEK | 17.49% |
| 2019 | -21.45 Million SEK | -52.73% |
| 2018 | -14.04 Million SEK | -5.93% |
| 2017 | -13.26 Million SEK | -16.06% |
| 2016 | -11.42 Million SEK | -9.64% |
| 2015 | -10.42 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q4 | -13.63 Million SEK | -50.66% |
| 2024 Q1 | -10.16 Million SEK | -13.37% |
| 2024 Q2 | -10.39 Million SEK | -2.31% |
| 2024 Q3 | -9.03 Million SEK | 13.13% |
| 2023 Q3 | -11.27 Million SEK | 3.51% |
| 2023 Q1 | -9.07 Million SEK | -4.28% |
| 2023 FY | -41 Million SEK | -17.07% |
| 2023 Q4 | -8.96 Million SEK | 20.49% |
| 2023 Q2 | -11.68 Million SEK | -28.73% |
| 2022 Q3 | -9.41 Million SEK | 8.91% |
| 2022 Q1 | -4.68 Million SEK | 0.07% |
| 2022 Q2 | -10.33 Million SEK | -120.65% |
| 2022 Q4 | -8.7 Million SEK | 7.51% |
| 2022 FY | -35.02 Million SEK | -41.11% |
| 2021 Q3 | -6.45 Million SEK | 21.31% |
| 2021 FY | -24.82 Million SEK | -40.21% |
| 2021 Q1 | -5.47 Million SEK | -12.04% |
| 2021 Q2 | -8.2 Million SEK | -49.91% |
| 2021 Q4 | -4.68 Million SEK | 27.42% |
| 2020 Q4 | -4.88 Million SEK | -1.1% |
| 2020 Q3 | -4.83 Million SEK | -13.85% |
| 2020 Q2 | -4.24 Million SEK | -13.03% |
| 2020 Q1 | -3.75 Million SEK | 52.9% |
| 2020 FY | -17.7 Million SEK | 17.49% |
| 2019 Q1 | -5.44 Million SEK | -59.01% |
| 2019 FY | -21.45 Million SEK | -52.73% |
| 2019 Q3 | -4.59 Million SEK | -29.34% |
| 2019 Q4 | -7.97 Million SEK | -73.33% |
| 2019 Q2 | -3.55 Million SEK | 34.63% |
| 2018 Q4 | -3.42 Million SEK | -10.88% |
| 2018 FY | -14.04 Million SEK | -5.93% |
| 2018 Q1 | -3.21 Million SEK | 32.8% |
| 2018 Q2 | -4.32 Million SEK | -34.83% |
| 2018 Q3 | -3.08 Million SEK | 28.72% |
| 2017 Q4 | -4.77 Million SEK | -32.23% |
| 2017 Q1 | -2.46 Million SEK | -4.44% |
| 2017 Q2 | -2.4 Million SEK | 2.35% |
| 2017 Q3 | -3.61 Million SEK | -50.18% |
| 2017 FY | -13.26 Million SEK | -16.06% |
| 2016 Q1 | -3 Million SEK | 0.0% |
| 2016 FY | -11.42 Million SEK | -9.64% |
| 2016 Q4 | -2.35 Million SEK | 22.69% |
| 2016 Q3 | -3.05 Million SEK | -1.44% |
| 2016 Q2 | -3 Million SEK | 0.0% |
| 2015 FY | -10.42 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 82.661% |
| Ziccum AB (publ) | -21.56 Million SEK | -100.242% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -163.229% |
| BioArctic AB (publ) | 252.64 Million SEK | 117.088% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -5009.127% |
| Mendus AB (publ) | -100.65 Million SEK | 57.107% |
| Genovis AB (publ.) | 54.22 Million SEK | 179.618% |
| Intervacc AB (publ) | -93.57 Million SEK | 53.866% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -178.314% |
| Active Biotech AB (publ) | -46.48 Million SEK | 7.125% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 339.725% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 22.096% |
| Aptahem AB (publ) | -10.1 Million SEK | -327.245% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 86.572% |
| Kancera AB (publ) | -65.04 Million SEK | 33.624% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 67.93% |
| Fluicell AB (publ) | -26.87 Million SEK | -60.617% |
| Saniona AB (publ) | -81.06 Million SEK | 46.744% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -248.978% |
| Biovica International AB (publ) | -126.07 Million SEK | 65.756% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -1.57% |
| AcouSort AB (publ) | -17.48 Million SEK | -146.881% |
| Xintela AB (publ) | -57.23 Million SEK | 24.574% |
| Abliva AB (publ) | -96.54 Million SEK | 55.284% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 86.708% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -1131.73% |
| OncoZenge AB (publ) | -15.9 Million SEK | -171.489% |
| Amniotics AB (publ) | -29.07 Million SEK | -48.496% |
| 2cureX AB (publ) | -36.36 Million SEK | -18.725% |
| CombiGene AB (publ) | -36.3 Million SEK | -18.915% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -194.892% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 88.769% |
| Camurus AB (publ) | 532.35 Million SEK | 108.11% |
| Corline Biomedical AB | -1.78 Million SEK | -2314.548% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 76.117% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -3.572% |
| I-Tech AB | 24.43 Million SEK | 276.681% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 94.525% |
| Cyxone AB (publ) | -21.66 Million SEK | -99.308% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 59.258% |
| Biosergen AB | -27.26 Million SEK | -58.343% |
| Cantargia AB (publ) | -290.01 Million SEK | 85.114% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 76.117% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -152.524% |
| Nanologica AB (publ) | -69.96 Million SEK | 38.293% |
| SynAct Pharma AB | -224.49 Million SEK | 80.769% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 2.272% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -80.227% |
| LIDDS AB (publ) | -40.67 Million SEK | -6.142% |
| Lipum AB (publ) | -37.25 Million SEK | -15.886% |
| BioInvent International AB (publ) | -369.94 Million SEK | 88.33% |
| Alzinova AB (publ) | -16.52 Million SEK | -161.301% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 82.966% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -575.277% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 62.483% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -114.371% |
| Simris Alg AB (publ) | -36.63 Million SEK | -17.844% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 70.544% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 86.093% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 61.076% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -273.268% |